JP2012046489A5 - - Google Patents

Download PDF

Info

Publication number
JP2012046489A5
JP2012046489A5 JP2011151340A JP2011151340A JP2012046489A5 JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5 JP 2011151340 A JP2011151340 A JP 2011151340A JP 2011151340 A JP2011151340 A JP 2011151340A JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5
Authority
JP
Japan
Prior art keywords
cancer
cells
virus
use according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011151340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012046489A (ja
Filing date
Publication date
Priority claimed from AU2002953436A external-priority patent/AU2002953436A0/en
Application filed filed Critical
Publication of JP2012046489A publication Critical patent/JP2012046489A/ja
Publication of JP2012046489A5 publication Critical patent/JP2012046489A5/ja
Pending legal-status Critical Current

Links

JP2011151340A 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法 Pending JP2012046489A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
AU2002953436 2002-12-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004559490A Division JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Publications (2)

Publication Number Publication Date
JP2012046489A JP2012046489A (ja) 2012-03-08
JP2012046489A5 true JP2012046489A5 (https=) 2012-10-11

Family

ID=30004521

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004559490A Pending JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法
JP2011151340A Pending JP2012046489A (ja) 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004559490A Pending JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Country Status (11)

Country Link
US (2) US7485292B2 (https=)
EP (1) EP1581257B1 (https=)
JP (2) JP2006517189A (https=)
KR (1) KR101171295B1 (https=)
CN (2) CN1784242B (https=)
AU (1) AU2002953436A0 (https=)
CA (1) CA2510227C (https=)
ES (1) ES2463678T3 (https=)
NZ (1) NZ541230A (https=)
WO (1) WO2004054613A1 (https=)
ZA (1) ZA200505389B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
EP1843773A4 (en) * 2005-01-17 2008-07-30 Viralytics Ltd METHOD AND COMPOSITION FOR TREATING NEOPLASIA
WO2013157648A1 (ja) 2012-04-19 2013-10-24 国立大学法人九州大学 医薬組成物
PL2826856T3 (pl) * 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
WO2015080631A1 (en) * 2013-11-27 2015-06-04 Obschestvo S Ogranichennoy Otvetstvennost`Yu "Panacela Labs" Improved expression vector for toll-like receptor and agonist and use for treating cancer
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
JP7138946B2 (ja) 2016-09-27 2022-09-20 セイター セラピューティクス エルエルシー 最適化された腫瘍溶解性ウイルスおよびその使用
EP3610870A4 (en) 2017-03-31 2020-12-09 Ogata, Hisanobu METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
MX2021005448A (es) * 2018-11-13 2021-08-11 Oncorus Inc Polinucleotidos encapsulados y metodos de uso.
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113421A (en) * 1978-02-24 1979-09-05 Fumiaki Taguchi Large scale cultivation of virus
US5585254A (en) 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
JPH04504361A (ja) 1989-04-05 1992-08-06 ノバセル　コーポレイション 感染性標的化複製―欠陥ビリオン
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0591382A4 (en) 1991-06-24 1995-01-18 Univ New York DE NOVO CELL-FREE SYNTHESIS OF PICORNAVIRUS.
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
CN101618049A (zh) 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
EP1061806A4 (en) 1998-03-12 2001-09-12 Univ Pennsylvania REPLICATING VIRUS PRODUCING CELLS FOR TREATING MALIGNANCY
US6060316A (en) 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
ATE402713T1 (de) 1999-02-05 2008-08-15 Arch Dev Corp Genetisch manipulierte herpesviren zur behandlung von tumoren
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
IL148621A0 (en) 1999-09-17 2002-09-12 Pro Virus Inc Oncolytic virus
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
CN1382218A (zh) 1999-11-15 2002-11-27 昂尼克斯药物公司 溶瘤腺病毒
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AU6814601A (en) 2000-06-01 2001-12-11 Sloan Kettering Inst Cancer Use of mutant herpes viruses and anticancer agents in the treatment of cancer
JP2004519431A (ja) 2000-12-01 2004-07-02 ユニバーシティ・オブ・オタワ 腫瘍溶解性ウイルス
AU2002318104A1 (en) * 2001-01-05 2002-11-25 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
EP1406668A1 (en) 2001-05-02 2004-04-14 Ramot at Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
EP2213300B1 (en) 2001-05-09 2015-03-25 Takara Bio, Inc. Composition and method for treating cancer using herpes virus
HUP0400882A3 (en) 2001-05-11 2011-01-28 Wellstat Biologics Corp Oncolytic virus therapy
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
WO2003010306A1 (en) 2001-07-23 2003-02-06 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
CA2476724A1 (en) 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
AU2003258060B2 (en) 2002-03-27 2007-07-12 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
AU2003223089A1 (en) 2002-04-29 2003-11-17 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
JP5241059B2 (ja) 2002-05-09 2013-07-17 オンコリティクス バイオテク，インコーポレーテッド 腫瘍崩壊ウイルスを使用して疼痛を軽減するための方法
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
WO2005007824A2 (en) 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
MXPA06003318A (es) 2003-09-26 2006-06-08 Novartis Ag Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad.
US8114416B2 (en) 2004-03-11 2012-02-14 Viralytics Limited Modified oncolytic viruses
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US8080240B2 (en) 2004-10-21 2011-12-20 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Similar Documents

Publication Publication Date Title
JP2012046489A5 (https=)
Roy et al. Lycorine: A prospective natural lead for anticancer drug discovery
Marcucci et al. How to improve exposure of tumor cells to drugs—Promoter drugs increase tumor uptake and penetration of effector drugs
Qian et al. Berberine reverses breast cancer multidrug resistance based on fluorescence pharmacokinetics in vitro and in vivo
NZ717490A (en) Methods of treating cancer
Bouche Compression and entrapment neuropathies
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
JP2013155188A5 (https=)
JP2014530873A5 (https=)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
CO6382135A2 (es) Terapia especifica y medicamento que usan ligando de integrina para tratar cancer
HK1210699A1 (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
JP2018522028A5 (https=)
JP2014523398A5 (https=)
JP2015507020A5 (https=)
JP2015506352A5 (https=)
JP2015044878A5 (https=)
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
JP2017516842A5 (https=)
CN103239464A (zh) 淫羊藿次苷ii在制备肿瘤化疗药物增敏剂中的用途
JP2015500286A5 (https=)
Isakoff et al. Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer
Mierzejewska et al. Novel evidence that hematopoietic stem/progenitor cells (HSPCs) are mobilized during hemolysis in an erythrocyte lysis-derived, sphingosine-1-phosphate (S1P)-dependent manner—the crucial involvement of complement cascade (CC) activation and attenuation of CXCR4 retention signaling
Marzuillo et al. Ondasetron Is More Likely Than Ketamine to Cause Ventricular Tachycardia